BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20168159)

  • 21. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fungemia associated with left ventricular assist device support.
    Bagdasarian NG; Malani AN; Pagani FD; Malani PN
    J Card Surg; 2009; 24(6):763-5. PubMed ID: 20078725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.
    Colombo AL
    Braz J Infect Dis; 2000 Jun; 4(3):113-8. PubMed ID: 10934493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital.
    Baran J; Muckatira B; Khatib R
    Scand J Infect Dis; 2001; 33(2):137-9. PubMed ID: 11233850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Epidemiology of fungemia in a university hospital; therapeutic incidence].
    Pavese P; Brion JP; Lebeau B; Grillot R; Ambroise-Thomas P
    Pathol Biol (Paris); 1999 May; 47(5):579-83. PubMed ID: 10418046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society.
    Yamamura DL; Rotstein C; Nicolle LE; Ioannou S
    CMAJ; 1999 Feb; 160(4):493-9. PubMed ID: 10081465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azole resistance of Candida glabrata in a case of recurrent fungemia.
    Posteraro B; Tumbarello M; La Sorda M; Spanu T; Trecarichi EM; De Bernardis F; Scoppettuolo G; Sanguinetti M; Fadda G
    J Clin Microbiol; 2006 Aug; 44(8):3046-7. PubMed ID: 16891541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
    Wilson AG; Micek ST; Ritchie DJ
    Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome.
    Krcméry V; Spánik S; Grausová S; Trupl J; Krupová I; Roidová A; Sálek T; Sufliarsky J; Mardiak J
    Neoplasma; 1998; 45(5):336-42. PubMed ID: 9921924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use.
    Hope W; Morton A; Eisen DP
    J Hosp Infect; 2002 Jan; 50(1):56-65. PubMed ID: 11825053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria.
    Presterl E; Daxböck F; Graninger W; Willinger B
    Clin Microbiol Infect; 2007 Nov; 13(11):1072-6. PubMed ID: 17725647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive candidiasis: turning risk into a practical prevention policy?
    Sobel JD; Rex JH
    Clin Infect Dis; 2001 Jul; 33(2):187-90. PubMed ID: 11418878
    [No Abstract]   [Full Text] [Related]  

  • 33. Epidemiological characteristics of fatal Candida krusei fungemia in immunocompromised febrile neutropenic children.
    Agirbasli H; Otlu B; Bilgen H; Durmaz R; Gedikoglu G
    Infection; 2008 Feb; 36(1):88-91. PubMed ID: 18084719
    [No Abstract]   [Full Text] [Related]  

  • 34. [Epidemiology of candidemia: a one-year prospective observational study in the west of France].
    Talarmin JP; Boutoille D; Tattevin P; Dargère S; Weinbreck P; Ansart S; Chennebault JM; Hutin P; Léautez-Nainville S; Gay-Andrieu F; Raffi F;
    Med Mal Infect; 2009 Dec; 39(12):877-85. PubMed ID: 19346088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal drug resistance: limited data, dramatic impact?
    Rogers TR
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():7-11. PubMed ID: 16701982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital.
    Luzzati R; Allegranzi B; Antozzi L; Masala L; Pegoraro E; Azzini A; Concia E
    Clin Microbiol Infect; 2005 Nov; 11(11):908-13. PubMed ID: 16216107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing patterns and trends in systemic fungal infections.
    Richardson MD
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i5-i11. PubMed ID: 16120635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent experience with fungaemia: change in species distribution and azole resistance.
    Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
    Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Candidemia in neonatal intensive care unit.
    Gupta N; Mittal N; Sood P; Kumar S; Kaur R; Mathur MD
    Indian J Pathol Microbiol; 2001 Jan; 44(1):45-8. PubMed ID: 12561995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit.
    Bassetti M; Ansaldi F; Nicolini L; Malfatto E; Molinari MP; Mussap M; Rebesco B; Bobbio Pallavicini F; Icardi G; Viscoli C
    J Antimicrob Chemother; 2009 Sep; 64(3):625-9. PubMed ID: 19622536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.